Multiple Myeloma

Stringent Complete Response in Multiple Myeloma Associated With Best Survival Outcomes

Patients able to achieve stringent complete response after undergoing autologous stem-cell transplantation for multiple myeloma achieved improved long-term outcomes, including overall survival and time to progression, compared with patients who achieved lesser levels of response.

Multiple Myeloma

Researchers from Japan believe they have identified a novel staging system based on hemoglobin and plasmacytoma that may help to stratify patients with multiple myeloma who are treated with novel therapeutics.

Carfilzomib given at a higher dose as a slow intravenous infusion over 30 minutes resulted in a very high response rate in a heavily pretreated myeloma population.

A comparison of melphalan, prednisone plus either thalidomide or lenalidomide found that patients assigned to lenalidomide had fewer grade 3 or higher toxicities and a better quality of life at the end of induction therapy.

Treatment of relapsed or refractory multiple myeloma with the three-drug combination of panobinostat/bortezomib/dexamethasone resulted in a nearly 4-month improvement in progression-free survival compared to treatment with bortezomib/dexamethasone alone.

Treatment with lenalidomide and dexamethasone improved quality-of-life measures in multiple myeloma patients, according to a study presented at the 2014 ASCO Annual Meeting.

Continuous therapy produces drastically better progression-free survival and overall survival outcomes in patients with multiple myeloma. A novel endpoint involving time to second progression is an important tool in evaluating this type of treatment in the future.

A phase II trial of propylene glycol-free melphalan in patients with multiple myeloma has met its primary endpoint, according to a statement released by the drug manufacturer.


Subscribe to Multiple Myeloma on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.